Lentiviral vectors have become the center of attention for its use as gene transfer vectors in gene therapy. Here, we have developed a new lentiviral production system for the clinical grade production of Lentiviral vectors on a large-scale serum-free suspension platform. This technology employs a newly developed propriety set of GMP reagents comprising of culture media, suspension cells, transfection reagent and boosting enhancers. With new culture media and media supplement, high density cell growth is optimized for maximum LVVs production. Customized lentivirus transfection reagents ensure highly efficient plasmids delivery. LVVs production is further elevated by the boosting enhancers. Taken together, our innovative system is able to deliver >2-3.0E+08 (TU/mL) functional titer with un-concentrated LVVs. We demonstrate that this system can be linearly adapted to bioreactors and wavebags system for large scale LVVs production without compromising the virus yield, which is ideal for industrial needs of gene therapy.
Biotechnology
Genetics
Molecular Biology
Cell Biology
Cancer Research
Cell Culture
Virology
Pcr/rt-Pcr/real-Time Pcr
Cancer Diagnostics
Molecular Diagnostics
Immunology
Medicine
Oncology
Microbiology
Antibodies
North America76%
Asia12%
Europe7%
South America2%
Africa2%
Website Visitors100%
Student16%
Facility/Department Manager16%
Scientist16%
Educator/Faculty13%
Executive13%
Research Scientist11%
Medical Doctor/Specialist8%
Microbiologist3%
Genetic Counselor3%
Lab Management3%
Academic Institution17%
Biotech Company10%
Life Science Company7%
Clinical Laboratory5%
Manufacturer & Biotech/pharma2%
Government2%
Ambulatory Care2%
Consultant2%
Media2%
Industrial Company2%
Manufacturer - Other2%
Medical School2%
Research Institute2%
Other7%